ENCORAFENIB

SynDRA canonical compound SYN0038042 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx
Primary target(s)	BRAF \| CCND1
Mechanism of action	RAF inhibitor \| serine/threonine kinase inhibitor
Indication	melanoma
Disease area	oncology

All known targets

braftovi
NVP-LGX818-NXA
Lgx-818
Lgx818
NVP-LGX-818-NXA
NVP-LGX818
Braftovi
LGX818
LGX 818
Encorafenib (LGX818)
UNII-8L7891MRB6
8L7891MRB6
Encorafenib [USAN:INN]
LGX-818(Encorafenib)
methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester
Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate
Braftovi (TN)
CARBAMIC ACID, N-((1S)-2-((4-(3-(5-CHLORO-2-FLUORO-3-((METHYLSULFONYL)AMINO)PHENYL)-1-(1-METHYLETHYL)-1H-PYRAZOL-4-YL)-2-PYRIMIDINYL)AMINO)-1-METHYLETHYL)-, METHYL ESTER
ENCORAFENIB [MI]
Encorafenib(LGX-818)
ENCORAFENIB [INN]
ENCORAFENIB [JAN]
ENCORAFENIB [USAN]
ENCORAFENIB [WHO-DD]
Encorafenib (JAN/USAN/INN)
GTPL7908
SCHEMBL8228295
CHEMBL3301612
DTXSID00155347
ENCORAFENIB [ORANGE BOOK]
BDBM221688
BCP08458
EX-A1587
MFCD25976758
NSC778304
NSC800093
s7108